MBX Biosciences (MBX) EBITDA (2023 - 2026)

MBX Biosciences has disclosed EBITDA across 4 years of filings, most recently posting -$24.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$24.4 million, down 2.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$87.3 million (down 18.88% YoY), and the FY2025 annual result was -$86.7 million, down 40.07% from the prior year.
• EBITDA came in at -$24.4 million for Q1 2026 at MBX Biosciences, down from -$21.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.8 million in Q4 2023 to a low of -$24.4 million in Q1 2026.
• The 4-year median for EBITDA is -$18.0 million (2024), against an average of -$17.5 million.
• Across the five-year window, EBITDA tumbled 92.6% in 2025 and retreated 2.21% in 2026, its largest moves.
• MBX Biosciences' EBITDA stood at -$8.8 million in 2023, then sank by 77.85% to -$15.6 million in 2024, then plunged by 40.24% to -$21.9 million in 2025, then fell by 11.3% to -$24.4 million in 2026.
• The last three EBITDA figures came in at -$24.4 million (Q1 2026), -$21.9 million (Q4 2025), and -$21.5 million (Q3 2025), per Business Quant data.